Company Profile
Immatics Stock Price, News & Analysis
- Ticker:
- IMTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany with major U
Stock performance
9.29 USD (+1.31%)
Close
Last updated: July 23, 2026
1.37B USD
Market cap
Why the stock is moving
IMTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Immatics is an immunotherapy company focused on T-cell receptor science and cancer immunotherapies. The company is building a platform around targeted immune recognition in oncology.
Geographic Base and Sector Classification
Headquartered in Germany with major U.S. market exposure and listed on NASDAQ as an ADR, Immatics has a global biotech footprint.
Business Model Characteristics
The model depends on clinical data, platform validation, and the ability to create differentiated immuno-oncology assets.
Position Within the Biotechnology Landscape
Immatics is a platform immunotherapy name with catalyst sensitivity to oncology data and translational progress.
Future catalysts
What matters most for Immatics from here is its latest development priorities. That matters because the company is now talking about SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in.... That is the piece most likely to shape sentiment in the near term.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
BRKR · Source: Bruker
- 02
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
DGX · Source: Quest Diagnostics
- 03
Molina Healthcare Reports Second Quarter 2026 Financial Results
MOH · Source: Molina Healthcare
- 04
Axon to Release Second Quarter 2026 Earnings on August 5, 2026
AXON · Source: Axon Enterprise, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immatics (IMTX)?
Immatics (IMTX) most recently closed at 9.29 USD, a +1.31% move versus the previous session.
What is the market cap of Immatics (IMTX)?
Immatics currently has a market capitalization of 1.37B USD on BioPharmSignal.
What does Immatics do?
Immatics is an immunotherapy company focused on T-cell receptor science and cancer immunotherapies. The company is building a platform around targeted immune recognition in oncology.
On which exchange is IMTX stock listed?
Immatics (IMTX) is associated with NASDAQ, Germany with major U, Biopharma.
What is Immatics?
What matters most for Immatics from here is its latest development priorities.
Which conditions is Immatics targeting with Immatics?
Immatics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immatics describe recent progress with Immatics?
What matters most for Immatics from here is its latest development priorities.
What is T-cell?
Immatics is an immunotherapy company focused on T-cell receptor science and cancer immunotherapies.